ES2557988T3 - Método para tratar enfermedades de próstata basado en el suministro local de principios activos - Google Patents

Método para tratar enfermedades de próstata basado en el suministro local de principios activos Download PDF

Info

Publication number
ES2557988T3
ES2557988T3 ES06724133.1T ES06724133T ES2557988T3 ES 2557988 T3 ES2557988 T3 ES 2557988T3 ES 06724133 T ES06724133 T ES 06724133T ES 2557988 T3 ES2557988 T3 ES 2557988T3
Authority
ES
Spain
Prior art keywords
active ingredients
diseases based
local supply
treat prostate
prostate diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES06724133.1T
Other languages
English (en)
Inventor
Hans Lennernäs
Bo Lennernäs
Jonas Hugosson
Niklas Axen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lidds AB
Original Assignee
Lidds AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lidds AB filed Critical Lidds AB
Application granted granted Critical
Publication of ES2557988T3 publication Critical patent/ES2557988T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Botany (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Un kit que comprende i) un primer componente que proporciona una dosis de refuerzo inicial de uno o más principios activos y/o profármacos seleccionados de fármacos antiandrógenos y/o un agente citostático; y ii) un segundo componente que comprende una composición farmacéutica de liberación controlada que comprende uno o más principios activos seleccionados de fármacos antiandrógenos y/o un agente citostático, en un vehículo cerámico biodegradable seleccionado de sulfato cálcico, para el tratamiento de enfermedades relacionadas con la próstata.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12
imagen13
imagen14
imagen15
imagen16
imagen17
imagen18
imagen19
imagen20
imagen21
imagen22
imagen23
imagen24
imagen25

Claims (1)

  1. imagen1
ES06724133.1T 2005-03-31 2006-03-31 Método para tratar enfermedades de próstata basado en el suministro local de principios activos Active ES2557988T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DK200500452 2005-03-31
DKPA200500452 2005-03-31
PCT/EP2006/003194 WO2006103112A2 (en) 2005-03-31 2006-03-31 Method for treating prostate diseases based on local delivery of active substances

Publications (1)

Publication Number Publication Date
ES2557988T3 true ES2557988T3 (es) 2016-02-01

Family

ID=35044589

Family Applications (1)

Application Number Title Priority Date Filing Date
ES06724133.1T Active ES2557988T3 (es) 2005-03-31 2006-03-31 Método para tratar enfermedades de próstata basado en el suministro local de principios activos

Country Status (17)

Country Link
US (1) US8936809B2 (es)
EP (1) EP1865924B1 (es)
JP (2) JP5635231B2 (es)
KR (2) KR20140014294A (es)
CN (1) CN101160116B (es)
AU (1) AU2006228675B2 (es)
CA (1) CA2602776C (es)
DK (1) DK1865924T3 (es)
ES (1) ES2557988T3 (es)
HU (1) HUE026158T2 (es)
IL (1) IL185690A0 (es)
MX (1) MX2007011908A (es)
NO (1) NO338679B1 (es)
PL (1) PL1865924T3 (es)
RU (1) RU2404747C2 (es)
WO (1) WO2006103112A2 (es)
ZA (1) ZA200708066B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101160116B (zh) * 2005-03-31 2011-12-07 利德斯公司 基于局部递送活性物质治疗前列腺疾病的方法
RU2536415C2 (ru) * 2008-11-27 2014-12-20 Лиддс Аб Применение карбоксиметилцеллюлозы для контроля выдавливаемости и времени затвердения композиций, содержащих один или более керамических материалов
GB2513675A (en) * 2011-04-05 2014-11-05 Edge Therapeutics Intraventricular drug delivery system for improving outcome after a brain injury affecting cerebral blood flow
RU2519407C2 (ru) * 2011-09-21 2014-06-10 Виктор Павлович Горелов Способ трансуретральной резекции предстательной железы, предшествующий брахитерапии рака простаты
GB201318862D0 (en) * 2013-10-25 2013-12-11 Glaxosmithkline Biolog Sa Calcium fluoride compositions
GB201318858D0 (en) * 2013-10-25 2013-12-11 Glaxosmithkline Biolog Sa Calcium fluoride compositions
ES2756301T3 (es) * 2014-08-19 2020-04-27 Univ California Implantes de administración localizada de fármacos y métodos de uso de los mismos
JP6921759B2 (ja) 2015-06-04 2021-08-18 クリティテック・インコーポレイテッド 捕集装置および使用法
AU2017246316B2 (en) 2016-04-04 2022-09-29 Crititech, Inc. Methods for solid tumor treatment
SG11201909840TA (en) 2017-06-09 2019-11-28 Crititech Inc Treatment of epithelial cysts by intracystic injection of antineoplastic particles
CA3063436A1 (en) 2017-06-14 2018-12-20 Crititech, Inc. Methods for treating lung disorders
CA3076919A1 (en) 2017-10-03 2019-04-11 Crititech, Inc. Local delivery of antineoplastic particles in combination with systemic delivery of immunotherapeutic agents for the treatment of cancer
US11911499B2 (en) 2019-11-07 2024-02-27 Resurge Therapeutics, Inc. System and method for prostate treatment
US11344526B2 (en) * 2020-03-20 2022-05-31 The Regents Of The University Of California Implantable drug delivery devices for localized drug delivery
US11173291B2 (en) * 2020-03-20 2021-11-16 The Regents Of The University Of California Implantable drug delivery devices for localized drug delivery
JP2023518061A (ja) * 2020-03-20 2023-04-27 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 局所的な薬物送達のための移植可能な薬物送達デバイス
US11338119B2 (en) * 2020-03-20 2022-05-24 The Regents Of The University Of California Implantable drug delivery devices for localized drug delivery
US11602516B1 (en) 2022-01-29 2023-03-14 Resurge Therapeutics Inc. Treating benign prostatic hyperplasia
US11957654B2 (en) 2022-01-29 2024-04-16 Resurge Therapeutics, Inc. Treating benign prostatic hyperplasia
WO2023147080A1 (en) * 2022-01-29 2023-08-03 Resurge Therapeutics, Inc. Benign prostatic hyperplasia treatment system

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4474813A (en) * 1980-10-24 1984-10-02 Schering Corporation Pharmaceutical preparations comprising flutamide
US5614206A (en) * 1995-03-07 1997-03-25 Wright Medical Technology, Inc. Controlled dissolution pellet containing calcium sulfate
US5795330A (en) * 1996-10-10 1998-08-18 Etex Corporation Mixing device
CA2268156C (en) * 1996-10-16 2007-05-29 Etex Corporation Bioceramic compositions
US6391336B1 (en) 1997-09-22 2002-05-21 Royer Biomedical, Inc. Inorganic-polymer complexes for the controlled release of compounds including medicinals
US5972384A (en) 1997-10-01 1999-10-26 University Of Maryland, Baltimore Use of biologically active glass as a drug delivery system
AU6318900A (en) 1999-08-05 2001-03-05 Takeda Chemical Industries Ltd. Pastes with the sustained release of osteogenesis promoter
US6497901B1 (en) * 2000-11-02 2002-12-24 Royer Biomedical, Inc. Resorbable matrices for delivery of bioactive compounds
US6645974B2 (en) * 2001-07-31 2003-11-11 Merck & Co., Inc. Androgen receptor modulators and methods for use thereof
US20030147936A1 (en) * 2002-02-07 2003-08-07 Velayudhan Sahadevan Prostatic hormonal implants treatment of prostate cancer
EP1660473A2 (en) * 2003-03-24 2006-05-31 Luitpold Pharmaceuticals, Inc. Xanthones, thioxanthones and acridinones as dna-pk inhibitors
GB0307082D0 (en) 2003-03-27 2003-04-30 Gyne Ideas Ltd Drug delivery device and method
CA2520475C (en) * 2003-04-03 2012-10-09 Jessie L.-S. Au Tumor-targeting drug-loaded particles
US20040224000A1 (en) 2003-05-05 2004-11-11 Romano Deghenghi Implants for non-radioactive brachytherapy of hormonal-insensitive cancers
EP1680089B1 (en) * 2003-10-22 2013-09-11 Lidds AB Composition comprising biodegradable hydrating ceramics for controlled drug delivery
CN101160116B (zh) * 2005-03-31 2011-12-07 利德斯公司 基于局部递送活性物质治疗前列腺疾病的方法

Also Published As

Publication number Publication date
WO2006103112A2 (en) 2006-10-05
US8936809B2 (en) 2015-01-20
NO20075490L (no) 2008-01-02
KR101380402B1 (ko) 2014-04-02
CN101160116B (zh) 2011-12-07
IL185690A0 (en) 2008-01-06
CN101160116A (zh) 2008-04-09
AU2006228675B2 (en) 2012-05-17
HUE026158T2 (en) 2016-05-30
ZA200708066B (en) 2016-07-27
EP1865924B1 (en) 2015-12-09
WO2006103112A3 (en) 2006-12-21
RU2007140243A (ru) 2009-05-10
JP5635231B2 (ja) 2014-12-03
MX2007011908A (es) 2008-02-07
NO338679B1 (no) 2016-09-26
US20080286205A1 (en) 2008-11-20
JP2013067639A (ja) 2013-04-18
CA2602776C (en) 2013-10-22
CA2602776A1 (en) 2006-10-05
PL1865924T3 (pl) 2016-06-30
EP1865924A2 (en) 2007-12-19
KR20140014294A (ko) 2014-02-05
DK1865924T3 (en) 2016-02-29
AU2006228675A1 (en) 2006-10-05
JP2008534546A (ja) 2008-08-28
KR20080002776A (ko) 2008-01-04
RU2404747C2 (ru) 2010-11-27

Similar Documents

Publication Publication Date Title
ES2557988T3 (es) Método para tratar enfermedades de próstata basado en el suministro local de principios activos
ES2649340T3 (es) Administración de fármacos activados por hipoxia y agentes antiangiogénicos para el tratamiento del cáncer
ES2487496T3 (es) Agente para aliviar el síndrome metabólico
ES2497494T3 (es) Método de tratamiento y prevención del hiperparatiroidismo secundario
ECSP077999A (es) Formulaciones de una sal de bupropion de liberación modificada
AR047928A1 (es) Derivados de tetrahidropiridoindol
CO6761350A2 (es) Derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituidos con aminoalcoholes que son de utilidad para tratar trastornos hiperproliferativos y enfermedades asociadas a la angiogenesis
PA8748101A1 (es) Benzoxazoles y oxazolopiridinas que son utiles como inhibidores de las cinasas janus
AR044007A1 (es) Metodos para el tratamiento de la enfermedad de parkinson
BRPI0509172A (pt) pelo menos uma entidade quìmica, composição farmacêutica, métodos para tratar um paciente, para inibir pelo menos uma enzima que utiliza atp, e para tratar pelo menos uma doença, uso de pelo menos uma entidade quìmica, e, método para a fabricação de um medicamento
CL2011000916A1 (es) Uso de una combinacion de un inhibidor de proteasoma epoxicetona peptidica o una sal farmaceutica aceptable del mismo, y uno o mas de otros agentes terapeuticos para tratar el cancer.
BRPI0516830A (pt) composições de droga de liberação sustentada convenientemente implantáveis
PA8580201A1 (es) Terapia de combinacion para enfermedades hiperproliferativas
BRPI0609393B8 (pt) usos de um composto 11-desóxi-prostaglandina
CL2008002224A1 (es) Composicion farmaceutica que comprende a) un compuesto seleccionado entre paclitaxel, docetaxel, ispinesib, tiazoloquinolina, entre otro, y b) compuestos inhibidores de aurora quinasa seleccionados entre derivados de imidazopirazina; uso de combinacion y de la composicion para tratar el cancer.
BR0316310A (pt) Composições farmacêuticas tendo um veìculo modificado
CL2010000188A1 (es) Metodo para el tratamiento de una infeccion en un sujeto que comprende la administracion de 9-[(2,2-dimetil-propilamino)-metil]-minociclina o de una sal de la misma; composicion farmaceutica que comprende dicho compuesto; y su uso.
CL2008001721A1 (es) Compuestos derivados de 17-beta-ciano-18 alfa-homo-19-nor-androst-4-eno; que presentan actividad gestagena y antimineralcorticoide; composicion farmaceutica; y uso en el tratamiento de trastornos pre-peri-y posmenopausicos y trastornos premenstruales.
AR055319A1 (es) Derivados de isoquinoleina, composiciones farmaceuticas y usos
UY29274A1 (es) Composicion farmaceutica para tratar la hipertension, que comprende telmisartano e hidroclorotiazida
BRPI0406796A (pt) Métodos para tratar hipertrofia prostática benigna, para reduzir um sintoma associado com a mesma, para reduzir o tamanho da próstata em um indivìduo humano e para profilaxia de bhp, composição farmacêutica oral de dose unitária, e, uso de lonidamina ou um análogo de lonidamina
CL2007003251A1 (es) Compuestos derivados de 1h-pirazoles sustituidos, inhibidores de reacciones catalizadas por una quinasa; su procedimiento de preparacion; composicion farmaceutica; compuestos intermediarios; uso de los compuestos principales, utiles en el tratamiento del cancer.
PE20040990A1 (es) Combinaciones de inhibidores de quinasa de erb b y farmacos antineoplasicos
AR056749A1 (es) Formulaciones de dosificacion oral de ibuprofeno organolepticamente aceptables metodos para su preparacion y uso
CL2007000789A1 (es) Compuestos derivados de malonamida, inhibidores de la gamma-secretasa; proceso de preparacion; composicion farmaceutica; y su uso en el tratamiento de la enfermedad de alzheimer.